Yuhchyau Chen, M.D., Ph.D.

Awards

2021
Fellow (FASTRO)
Sponsor: American Society for Radiation Oncology

2021
Fellow (FAAWR)
Sponsor: American Association for Women in Radiology

VIEW ALL expand_more

Clinical Trials

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Lead Researcher: Yuhchyau Chen

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.

View Study Details

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Lead Researcher: Yuhchyau Chen

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

View Study Details

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Lead Researcher: Yuhchyau Chen

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

View Study Details

Genotoxicity Assessment for Patients Receiving Large Field Irradiation

Lead Researcher: Yuhchyau Chen

The purpose of the research study is to evaluate an automated, laser-based technique for measuring DNA damage caused by radiation during cancer treatment in immature red blood cells.

View Study Details

Publications

Journal Articles

3/1/2023
McDonald AM, DeMora L, Yang ES, Hoyle JM, Lenzie A, Williams GR, Michalski JM, Yee D, Bahary JP, Den RB, Roach M, Dess R, Mishra MV, Valicenti RK, Lau HY, Marcrom SR, Souhami L, Mendez LC, Chen Y, Doncals DE, Pugh SL, Feng FY, Sandler HM. "Body composition and mortality in men receiving prostate radiotherapy: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126." Cancer.. 2023 Mar 1; 129(5):685-696. Epub 2022 Dec 29.

2023
Torous DK; Avlasevich S; Bemis JC; Howard T; Ware RE; Fung C; Chen Y; Sahsrabudhe D; MacGregor JT; Dertinger SD. "Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients". Environ Mol Mutagen. 2023; 64(3): 167-175.

2023
Raldow AC, Siker ML, Bonner JA, Chen Y, Liu FF, Metz JM, Movsas B, Potters L, Schultz CJ, Wilson E, Wang X, Romero T, Steinberg ML, Jagsi R. "Assessment of Differences in Academic Rank and Compensation by Gender and Race/Ethnicity Among Academic Radiation Oncologists in the United States." Advances in radiation oncology.. 2023 8(5):101210. Epub 2023 Mar 10.

Books & Chapters

2014
Chapter Title: Upper Respiratory and Digestive System: Pharynx, Larynx, and Xerostomia
Book Title: ALERT-Adverse Late Effects of Cancer Treatment
Author List: Mittal B; Chen Y; Eisbruch A
Edited By: Rubin P; Constine LS; Marks LB
Published By: Springer-Verlag 2014 in Berlin Heidelberg

2011
Chapter Title: Translational Research in Lung Cancer
Book Title: Advances in Radiation Oncology in Lung Cancer
Author List: Singh D; Bylund K; Chen Y
Edited By: Jeremic B
Published By: Springer-Verlag GmbH 2011 in Heidelberg

2007
Chapter Title: Advances in Chemoradiation Treatment of Locoregionally Advanced Non-small Cell Lung Cancer
Book Title: Lung Cancer: Translational & Emerging Therapies
Author List: Milano MT, Chen Y
Edited By: Pandya K, Brahmer JU, Hidalgo M
Published By: Taylor and Francis 2007 in New York, NY

VIEW ALL PUBLICATIONS

Reviews

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.